DDrare: Database of Drug Development for Rare Diseases

ID	Disease name (Link within this page)	Number of trials
46	Malignant rheumatoid arthritis	1

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00537667 (ClinicalTrials.gov)	August 2001	27/9/2007	The SPECTRA Study	A Single Centre, Open-Label, Randomised, Study to Evaluate the Effect of Anakinra (r-metHuIL-1ra) Alone and in Combination With PEGylated Recombinant Methionyl Human Soluble Tumour Necrosis Factor Receptor Type I (PEG sTNF-RI) on Synovial Inflammation in Subjects With Rheumatoid Arthritis.	Rheumatoid Arthritis	Drug: anakinra;Drug: anakinra and PEG sTNF-R1	Amgen	NULL	Terminated	18 Years	N/A	Both	22	Phase 2	NULL

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT00537667
(ClinicalTrials.gov)

August 2001

27/9/2007

The SPECTRA Study

A Single Centre, Open-Label, Randomised, Study to Evaluate the Effect of Anakinra (r-metHuIL-1ra) Alone and in Combination With PEGylated Recombinant Methionyl Human Soluble Tumour Necrosis Factor Receptor Type I (PEG sTNF-RI) on Synovial Inflammation in Subjects With Rheumatoid Arthritis.

Rheumatoid Arthritis

Drug: anakinra;Drug: anakinra and PEG sTNF-R1

Amgen

NULL

Terminated

18 Years

N/A

Both

Phase 2

NULL